The inflammatory microenvironment and microbiome in prostate cancer development

Nature Reviews Urology

Volumn 15, Issue 1, 2018, Pages 11-24

  Sfanos, Karen S ^a,b   Yegnasubramanian, Srinivasan ^a,b   Nelson, William G ^a,b   De Marzo, Angelo M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ENZALUTAMIDE; OXALIPLATIN; REACTIVE OXYGEN METABOLITE;

AGING; ANAEROCOCCUS; BACTEROIDES FRAGILIS; BACTEROIDES THETAIOTAOMICRON; BIFIDOBACTERIUM; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL POPULATION; CHLAMYDIA TRACHOMATIS; CHRONIC INFLAMMATION; CORYNEBACTERIUM; FINEGOLDIA; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; LACTOBACILLUS; MICROBIOME; NEISSERIA GONORRHOEAE; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE STRESS; PHENOTYPE; PREVOTELLA; PRIORITY JOURNAL; PROPIONIBACTERIUM; PROPIONIBACTERIUM ACNES; PROSTATE CANCER; PROSTATE EPITHELIUM CELL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATITIS; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS; TRICHOMONAS VAGINALIS; TUMOR MICROENVIRONMENT; VEILLONELLA; ANIMAL; ATROPHY; CELL TRANSFORMATION; EPITHELIUM; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; MALE; MICROBIOLOGY; MICROFLORA; PATHOLOGY; PROSTATE; PROSTATE TUMOR;

AGING; ANIMALS; ATROPHY; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIUM; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MALE; MICROBIOTA; PROSTATE; PROSTATIC NEOPLASMS; PROSTATITIS; TUMOR MICROENVIRONMENT;

EID: 85039868299     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2017.167     Document Type: Review

References (145)

1. Simons, J. W. Prostate cancer immunotherapy: beyond immunity to curability. Cancer Immunol. Res. 2, 1034-1043 (2014).
2. Topalian, S. L., Drake, C. G. &Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
3. De Marzo, A. M. et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 7, 256-269 (2007).
4. Sfanos, K. S., Hempel, H. A. &De Marzo, A. M. in Inflammation and Cancer, Advances in Experimental Medicine and Biology Vol. 816 (eds Aggarwal, B. B., Sung, B. &Gupta, S. B.) 153-181 (Springer, 2014).
5. Sfanos, K. S. &De Marzo, A. M. Prostate cancer and inflammation: the evidence. Histopathology 60, 199-215 (2012).
6. Hanahan, D. &Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
7. Sfanos, K. S., Isaacs, W. B. &De Marzo, A. M. Infections and inflammation in prostate cancer. Am. J. Clin. Exp. Urol. 1, 3-11 (2013).
8. Sutcliffe, S. Sexually transmitted infections and risk of prostate cancer: review of historical and emerging hypotheses. Future Oncol. 6, 1289-1311 (2010).
9. Platz, E. A. &De Marzo, A. M. Epidemiology of inflammation and prostate cancer. J. Urol. 171 (Suppl.), S36-S40 (2004).
10. Roberts, R. O., Bergstralh, E. J., Bass, S. E., Lieber, M. M. &Jacobsen, S. J. Prostatitis as a risk factor for prostate cancer. Epidemiology 15, 93-99 (2004).
11. Palapattu, G. S. et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26, 1170-1181 (2005).
12. Dennis, L. K., Lynch, C. F. &Torner, J. C. Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78-83 (2002).
13. Platz, E. A. et al. A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: linked PCPT and SELECT cohorts. Cancer Epidemiol. Biomarkers Prev. http://dx.doi. org/10.1158/1055-9965.EPI-17-0503 (2017).
14. Josef Marx, F. &Karenberg, A. History of the term prostate. Prostate 69, 208-213 (2009).
15. Bostwick, D. G., de la Roza, G., Dundore, P., Corica, F. A. &Iczkowski, K. A. Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate 55, 187-193 (2003).
16. Dikov, D., Bachurska, S., Staikov, D. &Sarafian, V. Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate. Prostate 75, 1074-1084 (2015).
17. Galli, S. J., Grimbaldeston, M. &Tsai, M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8, 478-486 (2008).
18. Fujii, T. et al. Immunohistochemical analysis of inflammatory cells in benign and precancerous lesions and carcinoma of the prostate. Pathobiology 80, 119-126 (2013).
19. Sfanos, K. S., Wilson, B. A., De Marzo, A. M. &Isaacs, W. B. Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. Proc. Natl Acad. Sci. USA 106, 3443-3448 (2009).
20. Difuccia, B., Keith, I., Teunissen, B. &Moon, T. Diagnosis of prostatic inflammation: efficacy of needle biopsies versus tissue blocks. Urology 65, 445-448 (2005).
21. Strasner, A. &Karin, M. Immune infiltration and prostate cancer. Front. Oncol. 5, 128 (2015).
22. Gurel, B. et al. Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol. Biomarkers Prev. 23, 847-856 (2014).
23. Nickel, J. C., Downey, J., Young, I. &Boag, S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 84, 976-981 (1999).
24. Lanciotti, M. et al. The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. BioMed Res. Int. 2014, 6 (2014).
25. Sfanos, K. S. et al. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. Prostate 69, 1694-1703 (2009).
26. Kiniwa, Y. et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13, 6947-6958 (2007).
27. Miller, A. M. et al. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177, 7398-7405 (2006).
28. Davidsson, S. et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer. Mod. Pathol. 26, 448-455 (2013).
29. Sfanos, K. S. et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin. Cancer Res. 14, 3254-3261 (2008).
30. Woo, J. R. et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J. Transl Med. 12, 1-9 (2014).
31. Karja, V. et al. Tumour-infiltrating lymphocytes: a prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res. 25, 4435-4438 (2005).
32. Flammiger, A. et al. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur. J. Cancer 49, 1273-1279 (2012).
33. Ammirante, M., Luo, J.-L., Grivennikov, S., Nedospasov, S. &Karin, M. B-Cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464, 302-305 (2010).
34. Flammiger, A. et al. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS 120, 901-908 (2012).
35. Hempel, H. A. et al. Low intratumoral mast cells are associated with a higher risk of prostate cancer recurrence. Prostate 77, 412-424 (2017).
36. Lissbrant, I. et al. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int. J. Oncol. 17, 445-451 (2000).
37. Wang, W., Bergh, A. &Damber, J.-E. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin. Cancer Res. 11, 3250-3256 (2005).
38. Nonomura, N. et al. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 107, 1918-1922 (2011).
39. Richardsen, E., Uglehus, R. D., Due, J., Busch, C. &Busund, L. T. R. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology 53, 30-38 (2008).
40. Irani, J. et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Urology 54, 467-472 (1999).
41. McArdle, P. A. et al. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br. J. Cancer 91, 541-543 (2004).
42. Kennedy, R. &Celis, E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 222, 129-144 (2008).
43. Beyer, M. &Schultze, J. L. Regulatory T cells in cancer. Blood 108, 804-811 (2006).
44. Nelson, W. G., De Marzo, A. M. &Isaacs, W. B. Prostate cancer. N. Engl. J. Med. 349, 366-381 (2003).
45. O'Hagan, H. M. et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 20, 606-619 (2011).
46. O'Hagan, H. M., Mohammad, H. P. &Baylin, S. B. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet. 4, e1000155 (2008).
47. Yegnasubramanian, S. et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 68, 8954-8967 (2008).
48. Aryee, M. J. et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci. Transl Med. 5, 169ra110 (2013).
49. Mani, R. S. et al. Inflammation-induced oxidative stress mediates gene fusion formation in prostate cancer. Cell Rep. 17, 2620-2631 (2016).
50. Haffner, M. C. et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 42, 668-675 (2010).
51. Haffner, M. C., De Marzo, A. M., Meeker, A. K., Nelson, W. G. &Yegnasubramanian, S. Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin. Cancer Res. 17, 3858-3864 (2011).
52. van Leenders, G. J. et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am. J. Pathol. 162, 1529-1537 (2003).
53. De Marzo, A. M., Marchi, V. L., Epstein, J. I. &Nelson, W. G. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155, 1985-1992 (1999).
54. Wang, W., Bergh, A. &Damber, J. E. Increased p53 immunoreactivity in proliferative inflammatory atrophy of prostate is related to focal acute inflammation. APMIS 117, 185-195 (2009).
55. Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M. &Korsmeyer, S. J. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl Acad. Sci. USA 88, 6961-6965 (1991).
56. Gurel, B. et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod. Pathol. 21, 1156-1167 (2008).
57. Koh, C. M. et al. MYC and prostate cancer. Genes Cancer 1, 617-628 (2010).
58. Putzi, M. J. &De Marzo, A. M. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 56, 828-832 (2000).
59. Wang, W., Bergh, A. &Damber, J. E. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate 69, 1378-1386 (2009).
60. Nakayama, M. et al. Hypermethylation of the human glutathione S-transferase-φ gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163, 923-933 (2003).
61. De Marzo, A. M., Nelson, W. G., Bieberich, C. J. &Yegnasubramanian, S. Prostate cancer: new answers prompt new questions regarding cell of origin. Nat. Rev. Urol. 7, 650-652 (2010).
62. Liu, X. et al. Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate human prostate cancer and predict poor outcome. Cell Rep. 17, 2596-2606 (2016).
63. Vykhovanets, E. V., Resnick, M. I., MacLennan, G. T. &Gupta, S. Experimental rodent models of prostatitis: limitations and potential. Prostate Cancer Prostat. Dis. 10, 15-29 (2007).
64. Shinohara, D. B. et al. A mouse model of chronic prostatic inflammation using a human prostate cancer-derived isolate of Propionibacterium acnes. Prostate 73, 1007-1015 (2013).
65. Simons, B. W. et al. A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. J. Pathol. 235, 478-489 (2015).
66. Sfanos, K. S. et al. Bacterial prostatitis enhances 2-amino-1-methyl-6-phenylimidazo[4,5-β]pyridine (PhIP)-induced cancer at multiple sites. Cancer Prevention Res. 8, 683-692 (2015).
67. Kwon, O.-J., Zhang, L., Ittmann, M. M. &Xin, L. Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc. Natl Acad. Sci. USA 111, E592-E600 (2014).
68. Olsson, J. et al. Chronic prostatic infection and inflammation by Propionibacterium acnes in a rat prostate infection model. PLoS ONE 7, e51434 (2012).
69. Elkahwaji, J. E., Zhong, W., Hopkins, W. J. &Bushman, W. Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis. Prostate 67, 14-21 (2007).
70. Khalili, M. et al. Loss of Nkx3.1 expression in bacterial prostatitis. Am. J. Pathol. 176, 2259-2268 (2010).
71. Haverkamp, J. M. et al. An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. Prostate 71, 1139-1150 (2011).
72. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
73. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
74. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
75. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015).
76. Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375-384 (2015).
77. Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803-1813 (2015).
78. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
79. Borghaei, H. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373, 1627-1639 (2015).
80. Higano, C. S. et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679 (2009).
81. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
82. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
83. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700-712 (2014).
84. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
85. Harada, N. et al. Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. Sci. Rep. 6, 23001 (2016).
86. Nam, Y.-D., Kim, H. J., Seo, J.-G., Kang, S. W. &Bae, J.-W. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS ONE 8, e82659 (2013).
87. Fridman, W. H., Pagès, F., Sautès-Fridman, C. &Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
88. Galon, J. et al. Cancer classification using the Immunoscore: a worldwide task force. J. Transl Med. 10, 205-205 (2012).
89. Galon, J. et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J. Pathol. 232, 199-209 (2014).
90. Capone, M. et al. Immunoscore: a new possible approach for melanoma classification [abstract]. J. Immunother. Cancer 2 (Suppl. 3), P193 (2014).
91. Graff, J. N. et al. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7, 52810-52817 (2016).
92. Bishop, J. L. et al. PD-L1 is highly expressed in Enzalutamide resistant prostate cancer. Oncotarget 6, 234-242 (2015).
93. Martin, A. M. et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostat. Dis. 18, 325-332 (2015).
94. Gevensleben, H. et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin. Cancer Res. 22, 1969-1977 (2016).
95. Abcam. Anti-PD-L1 antibody [EPR1161(2)] ab174838. Abcam http://www.abcam.com/pd-l1-antibody-epr11612-ab174838.html (2017).
96. Ebelt, K. et al. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur. J. Cancer 45, 1664-1672 (2009).
97. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263-274 (2005).
98. Vétizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079-1084 (2015).
99. Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967-970 (2013).
100. Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971-976 (2013).
101. Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084-1089 (2015).
102. Marchiando, A. M., Graham, W. V. &Turner, J. R. Epithelial barriers in homeostasis and disease. Annu. Rev. Pathol. 5, 119-144 (2010).
103. Peterson, L. W. &Artis, D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat. Rev. Immunol. 14, 141-153 (2014).
104. Gatti, G. et al. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate 69, 1387-1397 (2009).
105. Gambara, G. et al. Toll-like receptors in prostate infection and cancer between bench and bedside. J. Cell. Mol. Med. 17, 713-722 (2013).
106. Manning, M. L., Williams, S. A., Jelinek, C. A., Kostova, M. B. &Denmeade, S. R. Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma. J. Immunol. 190, 2567-2574 (2013).
107. Fowler, J. E. Jr &Mariano, M. Longitudinal studies of prostatic fluid immunoglobulin in men with bacterial prostatitis. J. Urol. 131, 363-369 (1984).
108. Isaacs, J. T. Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate 4, 351-366 (1983).
109. Fair, W. R. &Parrish, R. F. Antibacterial substances in prostatic fluid. Prog. Clin. Biol. Res. 75A, 247-264 (1981).
110. Zdrodowska-Stefanow, B., Ostaszewska-Puchalska, I., Badyda, J. &Galewska, Z. The evaluation of markers of prostatic inflammation and function of the prostate gland in patients with chronic prostatitis. Arch. Immunol. Ther. Exp. 56, 277-282 (2008).
111. Fair, W. R., Couch, J. &Wehner, N. Prostatic antibacterial factor identity and significance. Urology 7, 169-177 (1976).
112. Hrbacek, J., Urban, M., Hamsikova, E., Tachezy, R. &Heracek, J. Thirty years of research on infection and prostate cancer: no conclusive evidence for a link. A systematic review. Urol. Oncol. 31, 951-965 (2014).
113. Sutcliffe, S. et al. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J. Urol. 175, 1937-1942 (2006).
114. Sutcliffe, S. et al. Prostate involvement during sexually transmitted infections as measured by prostate-specific antigen concentration. Br. J. Cancer 105, 602-605 (2011).
115. Milbrandt, M. et al. Insight into infection-mediated prostate damage: contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection. Prostate 77, 1325-1334 (2017).
116. Sfanos, K. S. et al. A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate 68, 306-320 (2008).
117. Cohen, R. J., Shannon, B. A., McNeal, J. E., Shannon, T. &Garrett, K. L. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J. Urol. 173, 1969-1974 (2005).
118. Mak, T. N., Yu, S. H., De Marzo, A. M., Bruggemann, H. &Sfanos, K. S. Multilocus sequence typing (MLST) analysis of Propionibacterium acnes isolates from radical prostatectomy specimens. Prostate 73, 770-777 (2013).
119. Sfanos, K. S. &Isaacs, W. B. An evaluation of PCR primer sets used for detection of Propionibacterium acnes in prostate tissue samples. Prostate 68, 1492-1495 (2008).
120. Yanamandra, K. et al. Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate. PLoS ONE 4, e5562 (2009).
121. Huang, W.-Y. et al. Sexually transmissible infections and prostate cancer risk. Cancer Epidemiol., Biomarkers Prevention 17, 2374-2381 (2008).
122. Taylor, M. L., Mainous, A. G. 3 rd &Wells, B. J. Prostate cancer and sexually transmitted diseases: a meta-analysis. Family Med. 37, 506-512 (2005).
123. Sutcliffe, S. et al. Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15, 939-945 (2006).
124. Sutcliffe, S. et al. Plasma antibodies against Chlamydia trachomatis, Human Papillomavirus, and Human Herpesvirus Type 8 in relation to prostate cancer: a prospective study. Cancer Epidemiol. Biomarkers Prev. 16, 1573-1580 (2007).
125. Anttila, T. et al. Chlamydial antibodies and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 14, 385-389 (2005).
126. Whiteside, S. A., Razvi, H., Dave, S., Reid, G. &Burton, J. P. The microbiome of the urinary tract-A role beyond infection. Nat. Rev. Urol. 12, 81-90 (2015).
127. Gottschick, C. et al. The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. Microbiome 5, 99 (2017).
128. Pearce, M. M. et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio 5, e01283-14 (2014).
129. Hilt, E. E. et al. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J. Clin. Microbiol. 52, 871-876 (2014).
130. Nelson, D. E. et al. Characteristic male urine microbiomes associate with asymptomatic sexually tansmitted infection. PLoS ONE 5, e14116 (2010).
131. Nelson, D. E. et al. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. PLoS ONE 7, e36298 (2012).
132. Santiago-Rodriguez, T. M., Ly, M., Bonilla, N. &Pride, D. T. The human urine virome in association with urinary tract infections. Front. Microbiol. 6, 14 (2015).
133. Nickel, J. C. et al. Assessment of the lower urinary tract microbiota during symptom flare in women with urologic chronic pelvic pain syndrome: a MAPP network study. J. Urol. 195, 356-362 (2015).
134. Dong, Q. et al. The microbial communities in male first catch urine are highly similar to those in paired urethral swab specimens. PLoS ONE 6, e19709 (2011).
135. Nickel, J. C. &Xiang, J. Clinical significance of nontraditional bacterial uropathogens in the management of chronic prostatitis. J. Urol. 179, 1391-1395 (2008).
136. Fouts, D. E. et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J. Transl Med. 10, 174 (2012).
137. Shrestha, E. et al. Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J. Urol. http://dx.doi.org/10.1016/j. juro.2017.08.001 (2017).
138. Davidsson, S. et al. Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer. Infect. Agent. Cancer 11, 26 (2016).
139. Nickel, J. C. et al. Search for microorganisms in men with urologic chronic pelvic pain syndrome: a culture-independent analysis in the MAPP research network. J. Urol. 194, 127-135 (2015).
140. Javurek, A. B. et al. Discovery of a novel seminal fluid microbiome and influence of estrogen receptor alpha genetic status. Sci. Rep. 6, 23027 (2016).
141. Horwitz, D. et al. Decreased microbiota diversity associated with urinary tract infection in a trial of bacterial interference. J. Infect. 71, 358-367 (2015).
142. Caini, S. et al. Sexually transmitted infections and prostate cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. 38, 329-338 (2014).
143. Kirby, R. S., Lowe, D., Bultitude, M. I. &Shuttleworth, K. E. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br. J. Urol. 54, 729-731 (1982).
144. Yu, H. et al. Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia. Arch. Med. Sci. 11, 385-394 (2015).
145. Krieger, J. N., Dobrindt, U., Riley, D. E. &Oswald, E. Acute Escherichia coli prostatitis in previously health young men: bacterial virulence factors, antimicrobial resistance, and clinical outcomes. Urology 77, 1420-1425 (2011).